MX2016005285A - Conjugados de somatostatina y sus analagos. - Google Patents

Conjugados de somatostatina y sus analagos.

Info

Publication number
MX2016005285A
MX2016005285A MX2016005285A MX2016005285A MX2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A
Authority
MX
Mexico
Prior art keywords
somatostatin
conjugates
analogs
hydrogels
carriers
Prior art date
Application number
MX2016005285A
Other languages
English (en)
Inventor
V Santi Daniel
Ashley Gary
l schneider Eric
Hearn Brian
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of MX2016005285A publication Critical patent/MX2016005285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Abstract

Se describen conjugados de portadores e hidrogeles para controlar la vida media biológica de somatostatina y sus análogos.
MX2016005285A 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos. MX2016005285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894226P 2013-10-22 2013-10-22
PCT/US2014/061844 WO2015061503A1 (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs

Publications (1)

Publication Number Publication Date
MX2016005285A true MX2016005285A (es) 2016-10-28

Family

ID=52993525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005285A MX2016005285A (es) 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos.

Country Status (10)

Country Link
US (2) US10086049B2 (es)
EP (1) EP3060230A4 (es)
JP (1) JP2016534064A (es)
KR (1) KR20160075665A (es)
CN (1) CN106232131A (es)
AU (1) AU2014340095A1 (es)
CA (1) CA2928407A1 (es)
MX (1) MX2016005285A (es)
SG (2) SG11201603115YA (es)
WO (1) WO2015061503A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118902A1 (en) * 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN111065623A (zh) * 2017-05-24 2020-04-24 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
EP3684414A4 (en) * 2017-09-19 2021-06-09 Immunwork Inc. PHARMACEUTICAL CONSTRUCTIONS WITH IMPROVED BINDING AFFINITY WITH ALBUMIN
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
KR20220074897A (ko) * 2019-09-30 2022-06-03 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 단백질-거대분자 접합체 및 이의 사용 방법
EP4073064A4 (en) * 2019-12-11 2024-01-24 Massachusetts Gen Hospital METHOD FOR IMAGING CELLS
CN114409736B (zh) * 2022-01-28 2023-09-15 中国科学院精密测量科学与技术创新研究院 一种基于两亲性寡肽的定相排列介质及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
EP2457564A1 (en) 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
KR20110025974A (ko) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
DK2306986T3 (en) 2008-06-26 2018-06-18 Prolynx Llc PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
US8640315B1 (en) 2009-10-28 2014-02-04 Robert E. Nikkel Rotating adapter assembly
PT2523653T (pt) * 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina
CN103025164B (zh) * 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
WO2013036847A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Hydrogels with biodegradable crosslinking
MX350929B (es) 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.

Also Published As

Publication number Publication date
CN106232131A (zh) 2016-12-14
US20180296648A1 (en) 2018-10-18
US10086049B2 (en) 2018-10-02
JP2016534064A (ja) 2016-11-04
EP3060230A4 (en) 2017-06-14
SG11201603115YA (en) 2016-05-30
AU2014340095A1 (en) 2016-05-26
US10413594B2 (en) 2019-09-17
SG10201803370XA (en) 2018-06-28
CA2928407A1 (en) 2015-04-30
KR20160075665A (ko) 2016-06-29
WO2015061503A1 (en) 2015-04-30
US20160271227A1 (en) 2016-09-22
EP3060230A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
MX2020014120A (es) Agonistas parciales del receptor de insulina.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
IN2013KO01129A (es)
JO3755B1 (ar) تركيبات تستوستيرون
IN2013DE00266A (es)
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
AU2014224814A8 (en) Novel halogen-substituted compounds
NZ630549A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
MY187959A (en) Reactor
IN2013KO01130A (es)
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
EP3747444A3 (en) Use of sedoheptulose as a nutritional supplement
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA103911U (ru) Средство с вазодилатирующей активностью
UA76716U (uk) 5,7-ДИМЕТИЛ-2-ОКСО-6-ФЕНІЛАЗО-ТІАЗОЛО[4,5-b]ПІРИДИН-3-ІЛГІДРАЗОНИ АЦЕТАТНОЇ КИСЛОТИ, ЩО ПРОЯВЛЯЮТЬ АНТИЕКСУДАТИВНУ ДІЮ
UA79072U (en) (4-tert-butylperoxy-4-methylpentyl)methacrylate
IN2013KO01440A (es)
IN2013KO01329A (es)
IN2013KO01319A (es)
UA88439U (ru) Применение таурина как вещества со стресс-протекторным действием
IN2015KN00386A (es)
UA72478U (ru) Применение полентара как средства фригопротекторного действия